Plasma Pharmacokinetics, Urinary Excretion, and Tissue Distribution of Platinum Following IV Administration of Cyclobutanedicarboxylatoplatinum-II and cis-Platinum to Rabbits

  • C. L. Litterst
Part of the Developments in Oncology book series (DION, volume 17)


Cisdiamminedichloroplatinum (Cisplatin) is an effective agent in the treatment of several human cancers (3). Its clinical effectiveness is limited, however, by dose limiting toxicities such as renal failure, nausea and vomiting, and hearing loss (8,10). Ever since the clinical introduction of cisplatin in the early 1970’s efforts have been underway to discover or develop additional platinum complexes that would have a greater therapeutic index, i.e. either greater antitumor activity with the same degree of toxicity, or less toxicity so that greater doses could be administered. It has been only recently that large scale clinical trials of several of the most promising analogs have been undertaken. Cyclobutanedicarboxylatoplatinum (II) (CBDCA; JM-8; NSC 241240) is one of the second generation analogs of cisplatin that is currently undergoing large scale clinical trials (1). In these early clinical studies, evaluation of the pharmacokinetics and renal excretion of this analog have been conducted but similar data have not yet appeared for animals. We have evaluted plasma decay, urinary and biliary excretion, and organ distribution of CBDCA at various times after a single IV administration of 2 different doses to rabbits and compared the behavior of CBDCA to cisplatin.


Large Scale Clinical Trial Plasma Pharmacokinetic Platinum Concentration Rabbit Plasma Plasma Decay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Calvert, AH, SJ Harland, DR Newell, ZH Siddik, AC Jones, TJ McElwain, S Raju, E Wiltshaw, IE Smith, JM Baker, MJ Peckham & KR Harrap. Cancer Chemother. Pharmacol. 9: 140 (1982).PubMedCrossRefGoogle Scholar
  2. 2.
    DeSimone, PA, RS Yancey, JJ Coupai, JD Butts, JD Hoeschele. Cancer Treat. Reports. 63: 951 (1979).Google Scholar
  3. 3.
    Durant, JR. In: Cisplatin, Current Status and New Developments (AW Prestayko, ST Crooke & SK Carter, Eds.) p.317 (1980).Google Scholar
  4. 4.
    Hoeschele JD & L Van Camp. Adv. Antimicrobial & Antineoplastic Chemother. II: 241 (1972).Google Scholar
  5. 5.
    Knott GD. MLAB — A Mathematical Modeling Tool. In: Computer Programs in Biomedical Research. Vol. 10(3): 271 (1981).CrossRefGoogle Scholar
  6. 6.
    Litterst, CL, TE Gram, RL Dedrick, AF Leroy & AM Guarino. Cancer Res. 36: 2340 (1976).PubMedGoogle Scholar
  7. 7.
    Litterst CL, IJ Torres & AM Guarino. Wadley Medical Bull. 7: 169 (1977).Google Scholar
  8. 8.
    Nakai, Y, K Knoishi, KC Chang, K Ohashi, N Morisaki, Y Minowa, A Morimoto. Acta Otolaryngol. 93: 227 (1982).PubMedCrossRefGoogle Scholar
  9. 9.
    Pretorius RG, ES Petrilli, C Kean, LC Ford, JD Hoeschele, LD Lagasse, Cancer Treat. Rep. 65: 1055 (1981).PubMedGoogle Scholar
  10. 10.
    Schaeppi, U, IA Heyman, RW Fleischman, H Rosenkrantz, V Ilevaki, R Phelan, DA Cooney & RD Davis. Tox. Appl. Pharmacol. 25: 230 (1973).CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • C. L. Litterst

There are no affiliations available

Personalised recommendations